Supernus Pharmaceuticals Receives Nasdaq Delisting Notice for $1 Stock Price Violation
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) filed an 8-K on November 2, 2026, disclosing receipt of a Nasdaq delisting notice due to its stock closing below $1 for 30 consecutive trading days. The company has 180 calendar days to regain compliance or face delisting.
51CFO view：Delisting risk demands CFOs lead Regulation FD-compliant investor communications, clarify revenue recognition timing and clinical milestone payment structures on earnings calls, and pre-draft Form 8-A amendments for potential reverse stock splits — now a core competency for U.S.-listed Chinese firms’ finance leaders.
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) filed an 8-K on November 2, 2026, disclosing receipt of a Nasdaq delisting notice due to its stock closing below $1 for 30 consecutive trading days. The company has 180 calendar days to regain compliance or face delisting.
Source：SEC EDGAR · 8-K 重大事项公告
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
Who owns SEC reporting and US GAAP?
Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments.
Read →
Who runs finance through a SPAC merger?
De-SPAC files F-1 / 424(b); merger audit and disclosure cadence differ.
Read →